RESUMO
PURPOSE OF REVIEW: Zinc is essential for multiple cellular functions including immunity. Many investigators have used zinc supplementation in an attempt to affect the outcome of various diseases. These efforts were aimed at either supporting immunity by zinc administration or correcting the zinc dependent immune functions in zinc deficient individuals. RECENT FINDINGS: In this review, recent findings of zinc supplementation in various diseases have been presented. Beneficial therapeutic response of zinc supplementation has been observed in the diarrhea of children, chronic hepatitis C, shigellosis, leprosy, tuberculosis, pneumonia, acute lower respiratory tract infection, common cold, and leishmaniasis. Zinc supplementation was effective in decreasing incidences of infections in the elderly, in patients with sickle cell disease (SCD) and decreasing incidences of respiratory tract infections in children. Zinc supplementation has prevented blindness in 25% of the elderly individuals with dry type of AMD. Zinc supplementation was effective in decreasing oxidative stress and generation of inflammatory cytokines such as TNF-alpha and IL-1beta in elderly individuals and patients with SCD. SUMMARY: Zinc supplementation has been successfully used as a therapeutic and preventive agent for many conditions. Zinc functions as an intracellular signal molecule for immune cells.
Assuntos
Anemia Falciforme/tratamento farmacológico , Antioxidantes/uso terapêutico , Infecções/tratamento farmacológico , Inflamação/tratamento farmacológico , Degeneração Macular/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Zinco/uso terapêutico , Idoso , Antioxidantes/farmacologia , Cegueira/prevenção & controle , Criança , Doença Crônica , Citocinas/biossíntese , Suplementos Nutricionais , Humanos , Sistema Imunitário/efeitos dos fármacos , Zinco/deficiência , Zinco/farmacologiaRESUMO
La talidomida se introdujo en la década del 50 como droga hipnótica, sedante y antiemética, especialmente indicada en mujeres gestantes durante el primer trimestre del embarazo. Se asociaron al uso del fármaco graves anormalidades congénitas y polineuropatías, por lo que se la retiró del mercadoen los años 60. Posteriormente se comprobaron propiedades inmunomoduladoras en pacientes con eritema nudoso lepromatoso, así como también efectos antiinflamatorios como lupus eritematoso discoide, enfermedad de Behcet, úlceras aftosas en pacientes con SIDA, enfermedad crónica injerto contra huésped, mieloma múltiple y neoplasia de órganos sólidos. Actualmente, con el desarrollo de nuevos fármacos análogos de la talidomida, que conservan sus propiedades terapéuticas sin presentar teratogenicidad, su aplicación futura es más promisoria (AU)
Assuntos
Humanos , Talidomida/uso terapêutico , Adjuvantes Imunológicos/uso terapêutico , Talidomida/efeitos adversos , Talidomida/farmacologia , Talidomida/normas , Sistema Imunitário/efeitos dos fármacos , Interações Medicamentosas , Eritema Nodoso/tratamento farmacológico , Hanseníase Virchowiana/tratamento farmacológico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , /tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Doença Enxerto-Hospedeiro , Artrite Reumatoide/tratamento farmacológico , Pioderma Gangrenoso/tratamento farmacológico , Prurigo/tratamento farmacológico , Mieloma Múltiplo/tratamento farmacológico , Neoplasias/tratamento farmacológicoRESUMO
Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer. Its effectiveness in the clinic has been ascribed to wide-ranging properties, including anti-TNF-alpha, T-cell costimulatory and antiangiogenic activity. Novel compounds with improved immunomodulatory activity and side effect profiles are also being evaluated. These include selective cytokine inhibitory drugs (SelCIDs), with greatly improved TNF-alpha inhibitory activity, and immunomodulatory drugs (IMiDs) that are structural analogs of thalidomide, with improved properties. A third group recently identified within the SelCID group, with phosphodiesterase type 4-independent activity, is in the process of being characterized in laboratory studies. This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV. We also describe the laboratory studies that have led to the characterization and development of SelCIDs and IMiDs into potentially clinically relevant drugs. Early trial data suggest that these novel immunomodulatory compounds may supercede thalidomide to become established therapies, particularly in certain cancers. Further evidence is required, however, to correlate the clinical efficacy of these compounds with their known immunomodulatory, antiangiogenic, and antitumor properties.
Assuntos
Adjuvantes Imunológicos , Inibidores da Angiogênese , Antivirais , Sistema Imunitário/efeitos dos fármacos , Talidomida , Adjuvantes Imunológicos/farmacologia , Inibidores da Angiogênese/imunologia , Inibidores da Angiogênese/farmacologia , Antivirais/imunologia , Antivirais/farmacologia , Infecções por HIV/tratamento farmacológico , Infecções por HIV/imunologia , Humanos , Neoplasias/tratamento farmacológico , Neoplasias/imunologia , Talidomida/análogos & derivados , Talidomida/imunologia , Talidomida/farmacologiaAssuntos
Clofazimina/farmacologia , Sistema Imunitário/efeitos dos fármacos , Hansenostáticos/farmacologia , Infecções por Mycobacterium/tratamento farmacológico , Absorção , Animais , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Clofazimina/química , Clofazimina/farmacocinética , Clofazimina/uso terapêutico , Meia-Vida , Humanos , Técnicas In Vitro , Hansenostáticos/química , Hansenostáticos/farmacocinética , Hansenostáticos/uso terapêutico , Hanseníase/tratamento farmacológico , Relação Estrutura-Atividade , Distribuição TecidualRESUMO
The sedative thalidomide was withdrawn from the market 30 years ago because of its teratogenic and neurotoxic adverse effects. The compound was later discovered to be extremely effective in the treatment of erythema nodosum leprosum, a complication of lepromatous leprosy. This effect is probably due to a direct influence on the immune system, because thalidomide possesses no antibacterial activity. The compound is presently used as an experimental drug in the treatment of a variety of diseases with an autoimmune character, including recurrent aphthosis of nonviral and nonfungal origin in human immunodeficiency virus (HIV) patients. This article reviews the most important chemical and pharmacokinetic properties of thalidomide. The possible mechanisms of the nonsedative effects of thalidomide with respect to the safety of its use in HIV patients are discussed. Because the mechanism of the immunomodulatory effect of thalidomide is unknown, the possibility that the administration of this compound will accelerate the deterioration of the immunological status of HIV patients cannot be excluded. Clinical evidence suggests that thalidomide may aggravate the condition of patients with preexisting peripheral neuropathy. Hypersensitivity reactions to thalidomide may occur more frequently in HIV patients than in other patient groups. Because of the teratogenic activity of thalidomide, reliable contraception must be provided to female patients of childbearing age. Before the introduction of thalidomide therapy to an HIV patient presenting with oral ulcers, a fungal or viral origin of the lesions should be excluded. Thalidomide should not be used in patients with preexisting HIV-related peripheral polyneuropathy, polyradiculopathy or encephalopathy. In patients experiencing a complete remission, the discontinuation of thalidomide treatment and its reintroduction in the case of a relapse are preferable to maintenance therapy.